Previous 10 | Next 10 |
Freightos Limited (CRGO) is expected to report $-0.14 for Q3 2023 Magyar Telekom Telecommunications ADR (MYTAY) is expected to report for Q3 2023 IMAC Holdings Inc. (BACK) is expected to report for Q1 2024 NewJersey Resources Corporation (NJR) is expected to report $0.3 for Q4 2023 ...
Freeline Therapeutics Holdings plc (FRLN) is expected to report $-0.2 for Q3 2023
Frontline plc (the “Company”) announces that its 2023 Annual General Meeting will be held on December 12, 2023. A copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F for 2022 can be found on our website at...
Frontline plc (the “Company”) advises that the 2023 Annual General Meeting of the Company will be held on December 12, 2023. The record date for voting at the Annual General Meeting is set to November 20, 2023. The notice, agenda and associated material will be distributed prior to ...
Substantial reduction in lyso-Gb1 substrate levels, an established biomarker of clinical response, observed in first patient treated with FLT201 Increases of several hundredfold over baseline in plasma GCase activity and normalization of cellular GCase levels continue to be observed in fi...
2023-10-18 12:10:20 ET More on Freeline Therapeutics Freeline Therapeutics Holdings plc (FRLN) Q2 2023 Earnings Call Transcript Freeline posts early data for gene therapy in Gaucher disease Freeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62M ...
2023-10-18 10:00:01 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further...
2023-10-18 08:21:09 ET Ardelyx ( ARDX ) +18% granted FDA nod for kidney disease therapy. Connexa Sports Technologies ( CNXA ) +14% . Spirit Aerosystems ( SPR ) +10% Boeing Reach Agreement to Support Production Stability. Freeline Therapeutic...
LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate, in patients with Gaucher disease Ty...
Please find enclosed the presentation in relation to Frontline plc´s investor call to be held on the webcast / conference call October 9, 2023 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. ...
News, Short Squeeze, Breakout and More Instantly...
Freeline Therapeutics Holdings plc Company Name:
FRLN Stock Symbol:
NASDAQ Market:
Freeline Therapeutics Holdings plc Website:
Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline’s GBA1 Parkinson’s disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the...
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...
Please find enclosed the presentation of Frontline plc´s fourth quarter 2023 results to be held on the webcast / conference call 29 February, 2024 at 15:00 CET. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act ...